Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

BACKGROUND: It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment. METHODS: All patients treated with BRAF/MEK inhibitors achieving CR and ceasing treatment before progression were identified. Clinical data at treatment initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlino, Matteo S, Vanella, Vito, Girgis, Christina, Giannarelli, Diana, Guminski, Alex, Festino, Lucia, Kefford, Richard F, Menzies, Alexander M, Long, Georgina V, Ascierto, Paolo A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129828/
https://www.ncbi.nlm.nih.gov/pubmed/27711085
http://dx.doi.org/10.1038/bjc.2016.321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129828/
https://www.ncbi.nlm.nih.gov/pubmed/27711085
http://dx.doi.org/10.1038/bjc.2016.321

Ejemplares similares